6- chloro- 2,3,4,9- tetrahydro- 1H- carbazole- 1- carboxamide

01/01/2019 - "Furthermore, we found that administration with a Sirt-1 inhibitor, Ex-527, significantly improved recipient survival and clinical scores, with no signs of tumor relapse. "
01/01/2020 - "Significant reduction in 2-[18F]BzAHA SUV and distribution volume in 9L tumors was observed after administration of EX-527, but not MC1568. "
11/01/2023 - "The anticancer potential of inhibiting SIRT1 was evaluated by examining the effects of the specific SIRT1 inhibitor EX527 (also known as Selisistat) or genetic silencing, either individually or in conjunction with standard chemotherapeutic agents, on a range of HPV+ cancer cells and a preclinical mouse model of HPV16-induced cancer. "
09/15/2020 - "Compound 3g, bearing a benzyl substituent, inhibited both sirtuins at micromolar concentration and was more cytotoxic than EX-527 on several cancer cell lines."
04/01/2022 - "SIRT1 can represent a candidate molecule to be targeted to protect ovarian follicles from alkylating agents and EX-527 could represent a potential fertoprotective agent for cancer patients."

06/01/2015 - "EX-527 abolished RSV-induced attenuation of microvascular inflammation in ob/ob septic mice. "
12/01/2017 - "The protective effects of ω-3 PUFAs against hepatic steatosis-induced inflammation was reversed by the treatment with Sirt1 inhibitor EX-527. "
01/01/2019 - "In addition, SIRT1 inhibition by EX-527 or Sirt1-siRNA completely abolished miR-34a-I's protection against HG-induced endothelial inflammation and oxidative stress. "
11/01/2023 - "And the inhibitory effects of SAA on inflammation and ferroptosis were reversed by SIRT1 inhibitor EX-527. "
10/15/2023 - "aureus-induced inflammation and ferroptosis were prevented by the SIRT1 inhibitor EX-527. "

01/01/2020 - "Selisistat (EX-527) reached phase III clinical trials for treatment of Huntington's Disease. "
03/01/2015 - "Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). "
03/01/2015 - "An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease."
03/01/2015 - "Selisistat (SEN0014196), a first-in-class SirT1 inhibitor, is being developed as a disease-modifying therapy for Huntington's disease. "

01/05/2022 - "Besides, EX-527 (SIRT1 inhibitor) treatment could partially reverse the protective effects of GLP against sepsis-induced cardiac dysfunction (all Ps < 0.01). "
12/01/2014 - "The aims of the present study were to explore the effect of EX-527, a selective Sirtuin 1 (SIRT1) inhibitor, on survival in the lethal model of CLP-sepsis and to assess the impact of the treatment on inflammatory cytokine production, coagulopathy, and bone marrow atrophy during severe sepsis. "

01/01/2019 - "Protective effects of ex-527 on cerebral ischemia-reperfusion injury through necroptosis signaling pathway attenuation."